Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigilanol Tiglate in Head and Neck Cancer
NCT05608876Phase 2Active, not recruiting
- Sponsor
- QBiotics Group Limited
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tigilanol tiglate in head and neck cancer (HNC), sponsored by QBiotics Group Limited. Primary endpoint: Tumour Response at 72 weeks. Started Nov 2022; status: active, not recruiting.
02
Drugs
tigilanol tiglate
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05608876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608876.